» Articles » PMID: 20876141

Allosteric Inhibition of Complement Function by a Staphylococcal Immune Evasion Protein

Overview
Specialty Science
Date 2010 Sep 30
PMID 20876141
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

The complement system is a major target of immune evasion by Staphylococcus aureus. Although many evasion proteins have been described, little is known about their molecular mechanisms of action. Here we demonstrate that the extracellular fibrinogen-binding protein (Efb) from S. aureus acts as an allosteric inhibitor by inducing conformational changes in complement fragment C3b that propagate across several domains and influence functional regions far distant from the Efb binding site. Most notably, the inhibitor impaired the interaction of C3b with complement factor B and, consequently, formation of the active C3 convertase. As this enzyme complex is critical for both activation and amplification of the complement response, its allosteric inhibition likely represents a fundamental contribution to the overall immune evasion strategy of S. aureus.

Citing Articles

The Inhibitory Effects of a Factor B-Binding DNA Aptamer Family Supersede the Gain of Function of Factor B Variants Associated with Atypical Hemolytic Uremic Syndrome.

Duan H, Zhang Y, Otis M, Drolet D, Geisbrecht B J Immunol. 2024; 213(11):1691-1702.

PMID: 39431879 PMC: 11573645. DOI: 10.4049/jimmunol.2400420.


Staphylococcal peroxidase inhibitor (SPIN): Residue-level investigation of the helical bundle domain.

Fatehi S, Herdendorf T, Ploscariu N, Geisbrecht B Arch Biochem Biophys. 2024; 756:110023.

PMID: 38705227 PMC: 11104426. DOI: 10.1016/j.abb.2024.110023.


A guide to complement biology, pathology and therapeutic opportunity.

Mastellos D, Hajishengallis G, Lambris J Nat Rev Immunol. 2023; 24(2):118-141.

PMID: 37670180 DOI: 10.1038/s41577-023-00926-1.


In Silico Genome-Scale Analysis of Molecular Mechanisms Contributing to the Development of a Persistent Infection with Methicillin-Resistant (MRSA) ST239.

Dmitrenko O, Chaplin A, Balbutskaya A, Pkhakadze T, Alkhovsky S Int J Mol Sci. 2022; 23(24).

PMID: 36555727 PMC: 9781258. DOI: 10.3390/ijms232416086.


Complement component C3: A structural perspective and potential therapeutic implications.

Geisbrecht B, Lambris J, Gros P Semin Immunol. 2022; 59:101627.

PMID: 35760703 PMC: 9842190. DOI: 10.1016/j.smim.2022.101627.


References
1.
Rooijakkers S, Wu J, Ruyken M, van Domselaar R, Planken K, Tzekou A . Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol. 2009; 10(7):721-7. PMC: 2729104. DOI: 10.1038/ni.1756. View

2.
Gros P, Milder F, Janssen B . Complement driven by conformational changes. Nat Rev Immunol. 2007; 8(1):48-58. DOI: 10.1038/nri2231. View

3.
Janssen B, Christodoulidou A, McCarthy A, Lambris J, Gros P . Structure of C3b reveals conformational changes that underlie complement activity. Nature. 2006; 444(7116):213-6. DOI: 10.1038/nature05172. View

4.
Herbert A, Uhrin D, Lyon M, Pangburn M, Barlow P . Disease-associated sequence variations congregate in a polyanion recognition patch on human factor H revealed in three-dimensional structure. J Biol Chem. 2006; 281(24):16512-20. DOI: 10.1074/jbc.M513611200. View

5.
Harris C, Abbott R, Smith R, Morgan B, Lea S . Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). J Biol Chem. 2004; 280(4):2569-78. DOI: 10.1074/jbc.M410179200. View